PMID- 36276430
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221025
IS  - 1176-6328 (Print)
IS  - 1178-2021 (Electronic)
IS  - 1176-6328 (Linking)
VI  - 18
DP  - 2022
TI  - Blood and CSF Homocysteine Levels in Alzheimer's Disease: A Meta-Analysis and 
      Meta-Regression of Case-Control Studies.
PG  - 2391-2403
LID - 10.2147/NDT.S383654 [doi]
AB  - OBJECTIVE: Hyperhomocysteinemia (HHcy), as an important risk factor for 
      Alzheimer's disease (AD), would aggravate cognitive dysfunction. This study aimed 
      to investigate whether and to what degree the homocysteine (Hcy) levels in blood 
      and cerebrospinal fluid (CSF) were elevated in AD patients compared with healthy 
      controls and to explore the factors related to the elevated Hcy levels in AD 
      patients. METHODS: PubMed and Embase databases were searched to identify eligible 
      studies, and study quality was evaluated using the Newcastle-Ottawa Quality 
      Assessment Scale. Ratio of mean (RoM) Hcy concentrations was used as a measure of 
      fold-change between AD patients and healthy control subjects. RESULTS: We 
      identified 35 eligible studies, consisting a total of 2172 patients with AD and 
      2289 healthy controls. The pooled results showed that patients with AD had a 
      significantly higher blood level of Hcy (RoM, 1.32; 95% CI, 1.25-1.40; p<0.001) 
      than controls did, with large heterogeneity across studies (I(2)=81.4%, p<0.001). 
      Hcy level in CSF did not differ significantly between patients with AD than 
      controls (RoM, 1.12; 95% CI, 0.90-1.39, p=0.293; I(2)=69.4%, p=0.02). A random 
      effects meta-regression analysis revealed that there was an inverse correlation 
      between the blood levels of Hcy and folate (p=0.006). There was no link found 
      between the blood levels of vitamin B(12,) or the Mini-Mental Status Examination 
      scores reflecting the degree of cognitive impairment, and blood levels of Hcy. 
      CONCLUSION: Regardless of dementia severity, there is an approximate one-third 
      increase in blood Hcy in AD patients, which is robustly associated with a 
      decreased level of blood folate in AD, but not with that of blood vitamin B(12) 
      nor the degree of dementia. Future investigation on the cause-and-effect link 
      between Hcy and folate is warranted to clarify this issue.
CI  - (c) 2022 Zhang et al.
FAU - Zhang, Ling
AU  - Zhang L
AD  - School of Basic Medicine, Gannan Medical University, Ganzhou, People's Republic 
      of China.
FAU - Xie, Xinhua
AU  - Xie X
AD  - Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular 
      Diseases of Ministry of Education, Gannan Medical University, Ganzhou, People's 
      Republic of China.
FAU - Sun, Yangyan
AU  - Sun Y
AD  - School of Basic Medicine, Gannan Medical University, Ganzhou, People's Republic 
      of China.
FAU - Zhou, Futao
AU  - Zhou F
AUID- ORCID: 0000-0003-4872-7826
AD  - School of Basic Medicine, Gannan Medical University, Ganzhou, People's Republic 
      of China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221017
PL  - New Zealand
TA  - Neuropsychiatr Dis Treat
JT  - Neuropsychiatric disease and treatment
JID - 101240304
PMC - PMC9586177
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - homocysteine
OT  - meta-regression
COIS- The authors declare no conflicts of interest in this work.
EDAT- 2022/10/25 06:00
MHDA- 2022/10/25 06:01
PMCR- 2022/10/17
CRDT- 2022/10/24 04:17
PHST- 2022/07/25 00:00 [received]
PHST- 2022/09/25 00:00 [accepted]
PHST- 2022/10/24 04:17 [entrez]
PHST- 2022/10/25 06:00 [pubmed]
PHST- 2022/10/25 06:01 [medline]
PHST- 2022/10/17 00:00 [pmc-release]
AID - 383654 [pii]
AID - 10.2147/NDT.S383654 [doi]
PST - epublish
SO  - Neuropsychiatr Dis Treat. 2022 Oct 17;18:2391-2403. doi: 10.2147/NDT.S383654. 
      eCollection 2022.